Among targeted therapies, the EGFR TKIs, erlotinib and gefitinib are the most promising agents and have been shown in phase II trials to be active and well tolerated as first-line treatment of advanced NSCLC in the elderly. Here, EGFR is linked to non-small cell lung carcinoma.